Otsuka Announces Landmark Phase 3 VISIONARY Results for VOYXACT in IgA Nephropathy, Published in NEJM

Otsuka Pharmaceutical has announced the final two-year results from the Phase 3 VISIONARY study, demonstrating that VOYXACT® (sibeprenlimab-szsi) significantly stabilized kidney function and reduced the risk of disease progression and kidney failure in adults with primary immunoglobulin A nephropathy (IgAN). The study, with results published in The New England Journal of Medicine, showed a 97.1% reduction in the risk of a composite kidney outcome event compared to placebo. This data supports the role of selective APRIL inhibition as a disease-modifying treatment and suggests a redefinition of the treatment paradigm for IgAN.